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Abstract
Purpose of Review Aortic valve disease is the most common
form of heart valve disease in developed countries. Imaging
remains central to the diagnosis and risk stratification of pa-
tients with both aortic stenosis and regurgitation and has tra-
ditionally been performed with echocardiography. Indeed,
echocardiography remains the cornerstone of aortic valve im-
aging as it is cheap, widely available and provides critical
information concerning valve hemodynamics and ventricular
function.
Recent Findings Whilst diagnostic in the vast majority of
patients, echocardiography has certain limitations including
operator variability, potential for measurement errors and
internal inconsistencies in severity grading. In particular,
low-gradient severe aortic stenosis is common and chal-
lenging to diagnose. Aortic valve imaging may therefore
be improved with alternative and complimentary
multimodality approaches.
Summary This review investigates established and novel tech-
niques for imaging both the aortic valve and the myocardial
remodelling response including echocardiography, computed
tomography, cardiovascular magnetic resonance and positron
emission tomography. Moreover, we examine how the
complementary information provided by each modality may
be used in both future clinical practice and the research arena.
Keywords Valve . Stenosis . Regurgitation .Magnetic
resonance imaging . Echocardiography . Computed
tomography . Positron emission tomography
Introduction
Aortic valve disease is the most common valvular heart dis-
ease in the developed world [1]. In particular, calcific aortic
stenosis is responsible for considerable morbidity and mortal-
ity [2]. Aortic stenosis (AS) was once thought to be related to
simple Bwear and tear^ as a result of advancing age but is
increasingly understood to be a highly regulated process with
some similarities to atherosclerosis. An initiating event is be-
lieved to cause endothelial damage, inflammatory cell infiltra-
tion and initiation of calcification. A progressive cycle of cal-
cium deposition in the valve leaflets then occurs leading to an
inexorable march towards severe aortic stenosis and the de-
velopment of symptoms and heart failure unless aortic valve
replacement (AVR) is performed [3]. Aortic regurgitation
(AR) is common in calcific aortic valve disease but may also
be caused by other pathology affecting the valve, such as
endocarditis, or the aortic root, causing functional regurgita-
tion as in hypertension, Marfan syndrome, annulo-aortic
ectasia, collagen vascular disease and aortic dissection.
In both aortic stenosis and regurgitation, imaging of the
aortic valve is critical in establishing a diagnosis, grading se-
verity and informing the timing of valvular intervention. In
addition, the importance of the myocardial remodelling re-
sponse to these forms of valve disease is increasingly appre-
ciated [4]. Aortic stenosis leads to a pressure-overloaded left
ventricle, resulting in the left ventricular hypertrophy (LVH),
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which normalises wall stress according to Laplace’s law. This
is initially adaptive, but decompensation eventually occurs
leading to the development of heart failure, symptoms and
adverse events. Current clinical guidelines suggest valvular
intervention in severe aortic stenosis when there is evidence
of LV decompensation as indicated by the development of
either symptoms or impaired LVejection fraction (EF) [5, 6].
However, assessment of symptoms in elderly patients who
often have multiple comorbidities can be challenging whilst
impairment of LV systolic function occurs late in the disease
process [7] and is often irreversible [8, 9]. There is therefore a
need for more objective assessments of the left ventricular
decompensation. Similarly, in aortic regurgitation, the left
ventricle dilates in response to chronic volume overload in
an eccentric hypertrophic response.With time, this decompen-
sation of this remodelling response also occurs, leading to
heart failure, symptoms and adverse events in the absence of
treatment. Current guidelines advocate valve replacement in
the presence of severe aortic regurgitation and symptoms or
when LV dilatation reaches certain thresholds.
In this review, we will describe how modern advances in
non-invasive imaging might optimise assessments of aortic
valve stenosis and regurgitation as well as how the left ven-
tricular remodels in response to those lesions. In particular, the
established role of echocardiography will be explored along-
side emergingmodalities such as computed tomography (CT),




Transthoracic echocardiography (TTE) is the clinical imaging
modality of choice for assessing aortic stenosis and has been
since in the 1980s when it supplanted invasive catheter-based
measurements. It is safe, non-invasive and widely available,
allowing direct visualisation of aortic valve anatomy (e.g. bi-
cuspid vs. trileaflet), function and hemodynamics whilst also
facilitating measurement of the left ventricular wall thickness,
cavity dimensions and both systolic and diastolic function.
Doppler echocardiography provides information on aortic
valve hemodynamics that is not readily available using other
imaging modalities. Simple assessments of both peak and
mean velocities through the aortic valve (Fig. 1) are used to
calculate peak andmean pressure gradients using the modified
Bernoulli formula as well as the aortic valve area (AVA) using
the continuity equation. The latter is flow independent and
therefore often essential for diagnostic accuracy particularly
in low-flow states [10]. Current guidelines recommend grad-
ing haemodynamic severity of aortic stenosis on the basis of
the combined information provided by the peak velocity (AV
Vmax), the mean gradient and the aortic valve area [5, 6].
Whilst this combined approach is effective in the majority
of patients, it leads to a wide spectrum of diagnostic categories
and the potential for clinical confusion. Other potential limita-
tions of echocardiography are also being increasingly appreci-
ated. Firstly, acquisition of diagnostic acoustic windows can be
impossible in certain patients as can perfect alignment of the
Doppler probe with the direction of maximal blood flow
through the valve. In both circumstances, measurement errors
will be introduced. Secondly, echocardiography may have dif-
ficulty in measuring the left ventricular outflow tract (LVOT)
diameter with accuracy: a key component when using the con-
tinuity equation to calculate the aortic valve area. Indeed, echo
often underestimates the LVOT diameter due to either calcifi-
cation or its elliptical shape, and as the measurement is
squared, even small errors become magnified substantially.
The continuity equation also relies on several geometric as-
sumptions that frequently do not hold true in aortic stenosis
(such as a circular outflow tract and laminar flow profile),
introducing further error. Finally, internal inconsistencies exist
in the severity thresholds established in the clinical guidelines.
An AVA of 1.0 cm2 is sensitive but less specific for severe
aortic stenosis and in fact corresponds to a mean pressure gra-
dient of 30–35 mmHg [11], rather than the 40 mmHg cut-off
recommended [5, 6]. This in part may explain why between 20
and 30 % of patients with moderate or severe aortic stenosis
have discrepant assessments of disease severity depending on
the echocardiographic marker assessed [4, 12].
Fig. 1 Echocardiographic assessment of a patient with severe aortic
stenosis. a Short axis view showing heavily calcified leaflets. b
Parasternal long axis view showing large calcium deposit on right
coronary cusp with restricted valve opening. c Right sternal edge
continuous-wave Doppler with aortic valve velocity >4 m/s,
corresponding with severe stenosis
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LV Function and Mass
Echocardiography-derived LVejection fraction is used in clin-
ical guidelines to reflect LV systolic function. Impairment in
the EF below 50 % is an indication for valve intervention as
these patients have a poor outcome without surgery [8, 13].
However, a fall in ejection fraction is an insensitive measure of
LV systolic dysfunction in the presence of concentric remod-
elling and hypertrophy. Indeed, approximately one third of
patients with aortic stenosis and a normal EF have significant
evidence of LV systolic impairment when assessed by other
methods [14]. These alternative markers include global longi-
tudinal strain measurements, which have been shown to be of
prognostic importance in patients with severe aortic stenosis
and a normal ejection fraction [15].
Patients with aortic stenosis invariably develop the left ven-
tricular hypertrophy as the LV remodels to normalise wall
stress. The degree to which this occurs is not well correlated
to the haemodynamic severity of stenosis and is an indepen-
dent predictor of outcomes [16, 17•]. The LV hypertrophic
response should therefore be assessed separately. Concentric
remodelling geometry [18] and severe LVH [19] have been
associated with mortality following valve replacement whilst
increased LV mass is associated with cardiovascular morbidity
and mortality in patients with asymptomatic severe AS [17•].
Importantly, recent evidence from 1656 patients in the SEAS
trial showed that LV mass index was an independent predictor
of cardiovascular events and all-cause mortality [20••].
Low-Flow Low-Gradient Subtypes
The most challenging patients are those with discordant pa-
rameters of severity, most commonly characterised by a low
AVA and low transvalvular gradient. As discussed, there are
several possible explanations for this including measurement
error and internal inconsistencies in guideline thresholds.
However, in many patients, the discrepancy will not be due
to error but instead reflect a low-flow status related to an array
of different factors. Low flow is usually defined by a stroke
volume (SV) index of <35 ml/m2 although this cut-off is
somewhat arbitrary.
Classical Low-Flow Low-Gradient AS
In patients with severe aortic stenosis and LV systolic dys-
function, the stroke volume is low due to reduced myocardial
contractility. As a consequence, the gradient generated over
the aortic valve is relatively low (mean gradient <40 mmHg)
but the valve area is small <1.0 cm2 (low-flow low gradient
with reduced EF severe AS). It is important to differentiate
this condition from Bpseudo-severe AS,^ where the ventricle
is severely impaired due to an alternative pathology to the
extent that it cannot generate sufficient flow to completely
open the aortic valve. Low-dose dobutamine stress echocardi-
ography (DSE), as recommended in clinical guidelines [5, 6],
can differentiate between these; if the mean valve gradient
increases to >40 mmHg (or AV Vmax >4 m/s) and valve area
remains <1.0 cm2 with dobutamine stress, then severe AS has
been identified. These patients have a relatively low operative
mortality (5–7 % [21, 22]) and benefit from AVR [23].
Flow Reserve
Those patients who fail to increase their gradient with stress
echocardiography likely have no or reduced Bflow reserve^
which is defined as an increase in stroke volume of less than
20 % [24]. This group of patients has significantly higher
operative mortality (22–30 % [13, 21]), but those who survive
AVR have outcomes (improvement in EF and mortality) sim-
ilar to those with flow reserve [13, 25] and an improved prog-
nosis compared to similar patients managed medically [13].
There may be an increased future role for transcatheter aortic
valve implantation (TAVI) in this group given their high op-
erative risk.
Paradoxical Low-Flow Low-Gradient AS
These patients have low flow in the context of preserved ejec-
tion fraction, again leading to a picture of a reduced AVA
(<1.0 cm2) and low mean gradient (<40 mmHg). It is often
referred to as low-flow low-gradient normal EF or paradoxical
low-flow low-gradient aortic stenosis andwas first identified in
2007 [26]. Commonly, these patients are female and elderly,
with a small hypertrophied LV cavity as the cause of their low
stroke volume. A recent meta-analysis of 7459 patients and
other studies have indicated that mortality is increased in this
group [26, 27••, 28, 29] and reduced by valve intervention
[28–31]. However, this has not been observed consistently in
all trials [32]. Stress echocardiography has not been shown to
be helpful in these patients as they often exhibit restrictive
physiology due to diastolic dysfunction limiting any increase
in SV; however, aortic valve CT calcium scoring may aid in
discrimination [12]. Current clinical guidelines recommend
aortic valve intervention in this group if the patient is symp-
tomatic and the clinician feels that valve obstruction is the most
likely cause of symptoms based on the above parameters [5, 6].
Normal-Flow Low-Gradient AS
Patients with both a low AVA and low mean gradient in the
context of preserved EF and normal flow are a common
[27••] but under recognised group who are not represented
in clinical guidelines. Although this is heterogeneous group
that encompasses measurement errors, small body size or
inconsistencies in clinical guidelines [11], a significant pro-
portion have severe AS [12] and AVR appears to improve
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survival [31]. A recent large meta-analysis has demonstrat-
ed that these patients have outcomes similar to high-
gradient severe AS which are improved by AVR [27••].
Further research in this area is required.
Dimensionless Index
The dimensionless velocity index is a flow-independent vari-
able calculated by dividing the LVOT velocity-time integral
(VTI, or Vmax) by the AV VTI (or Vmax) without a need to
measure the LVOT diameter. A ratio of <0.25 indicates severe
stenosis and is particularly useful where LVOT measurement
is difficult to perform or in cases of inconsistent grading [33].
Advanced Echocardiography
In addition to demonstrating flow reserve in low-flow low-
gradient severe AS with a reduced ejection fraction, stress
echocardiography has also been shown to improve prognosti-
cation in asymptomatic high-gradient severe AS where an
increase in mean gradient of >20 mmHg on exercise stress
predicts a greater risk of developing symptoms and adverse
events [34, 35].
Transoesophageal echocardiography (TOE) can be of
use in aortic stenosis with planimetry of the AVA used as
an alternative measure of aortic stenosis severity. Whilst
planimetry remains difficult on 2D imaging due to extensive
calcification and difficulty ensuring position at the leaflet
tips, it appears more readily feasible on 3D TOE. A study of
307 patients with severe aortic stenosis compared valve
planimetry using 3D TOE with TTE-derived aortic valve
area. They showed that valve planimetry was possible in
92 % of patients (in the 8 % where it was not possible, this
was due to severe calcification) and that the two measure-
ments showed a good correlation (r = 0.85). However,
planimetred AVA measurements were consistently higher
than those calculated with the continuity equation [36].
Adjudicating disease severity using planimetry can there-
fore be difficult although in that context, an AVA<1.0 cm2 is
a strong indication of severe aortic stenosis and a potentially
useful arbitrator in cases of diagnostic uncertainty.
TOE also offers accurate assessment of the aortic root and
annulus dimensions and is frequently performed preoperative-
ly before aortic valve surgery. Similar measurements can be
made with CT imaging and the modality used differs between
centres. The use of intraoperative TOE is routine in many
cardiothoracic centres where it allows accurate assessment of
anatomy and optimisation of hemodynamics before establish-
ing cardiopulmonary bypass. Post-procedure, TOE can con-
firm satisfactory valve function, stable hemodynamics and
exclude complications such as outflow tract obstruction. A
number of observational studies suggest that intraoperative
TOE changes management in 11–18 % of patients may
improve outcome [37, 38] and may be cost-effective [39].
Intraoperative TOE has a class lla recommendation from the
most recent CC/AHA/ASE 2003 Guideline Update for the
Clinical Application of Echocardiography.
Pre-procedural imaging (TOE or CT) is essential prior to
TAVI to ensure correct prosthesis sizing, and real-time intra-
procedural TOE is often used to aid in device sizing and po-
sitioning [40, 41], although this is limited to trans-apical and
aortic approaches where the patient is under general anaesthet-
ic. Studies are conflicting but suggest that there is overall a
slight overestimation of annulus area with CT and underesti-
mation with TOE [42, 43]. 3D TOE is superior to 2D TOE and
offers similar results to CT in some studies [44].
Valvular Calcification
Although the mechanisms underlying valvular calcification
remain incompletely determined [3], its importance to disease
progression and adverse events was first identified in the sem-
inal studies by Rosenhek and colleagues [45••, 46••]. One
hundred and twenty-six patients with asymptomatic severe
aortic stenosis were followed up for 22 ± 18 months. Aortic
valve calcification was measured on a four-point ordinal scale
with moderate or severe calcification (a score of 3 or 4) being
the only independent predictor of AVR or mortality,
outperforming haemodynamic measures of severity.
Significant valve calcification is also associated with faster
disease progression, need for AVR and all-cause mortality in
patients with mild to moderate stenosis [46••]. Whilst severe
aortic valve calcification is considered a lla indication for
AVR in asymptomatic patients with severe AS, this technique
is in practice difficult to apply because of poor intra-observer
agreement as to the severity of calcification [47].
CT
CT Calcium Scoring
Calcium burden in the aortic valve can be more accurately
quantified on electrographically gated non-contrast computed
tomography (CT). The aortic valve CTcalcium score can then
be measured using the Agatston score (AU), which accounts
for both the density and volume of CT measured calcium and
correlates closely with the weight of calcium in explanted
aortic valves [47]. Aortic valve CT calcium scoring has dem-
onstrated excellent intra- and inter-observer and scan-rescan
reproducibility [47, 48] and correlates closely with echocar-
diographic measures of haemodynamic severity [47–49].
Importantly, recent data has demonstrated that the aortic valve
CT calcium score provides powerful prediction of disease
progression and prognosis [50–52].
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Severity Cut-Offs
Thresholds in CT calcium score for differentiating moderate
from severe aortic stenosis have recently been proposed in a
study of 451 patients with concordant grading of AS severity
on echocardiography and preserved ejection fraction.
Interestingly, these were different for males and females
(≥2065 AU for men and ≥1274 AU for women) even after
indexing to the aortic annulus area (≥476 AU/cm2 for men and
≥292 AU/cm2 for women). These thresholds were then ap-
plied to a larger cohort of 794 patients and demonstrated a
strong predictive value for all-cause mortality of incremental
value to echocardiographic parameters of ejection fraction and
stenosis severity [53••] (Fig. 2).
Aortic valve calcium scoring may be of particular use in
cases of low-flow low gradient with reduced EF [49, 54],
especially in the absence of flow reserve [47] where it can
be challenging to determine severity by echocardiography
alone. Further work is required to assess the validity of these
thresholds in alternative patient populations and to confirm
their predictive value. If these prove confirmatory, then we
believe CT calcium scoring will emerge as a clinically useful
and flow-independent adjuvant to standard echocardiography.
Improved AVA Calculation
The increasing use of CTangiography for valve sizing prior to
TAVI procedures has demonstrated that the LVOT is often
eccentric not circular. Indeed, a recent study of 269 patients
with severe AS undergoing CT demonstrated that the LVOT is
eccentric in 93 % of patients [55]. As a consequence, TTE
measures of the LVOT diameter can frequently result in un-
derestimation of the true AVA [56]. Using CT, CMR or indeed
3D echo to planimeter the LVOTarea could therefore improve
the accuracy of AVA calculations.
PET
PET is a novel imaging technique, which allows the activity of
specific disease processes to be measured in vivo. Recently,
this technique has employed two tracers to measure inflam-
mation (18F-fluorodeoxyglucose (18F-FDG)) and calcification
activity (18F-fluoride) in the valves of patients with aortic ste-
nosis. Hybrid PET/CT scanners then allow the activity of
these two key processes to be compared with the presence of
established regions of macrocalcification on CT.
18F-Fluoride
18F-fluoride has been used as a bone tracer for 50 years binding
to hydroxyapatite crystal and detecting regions of increased
bone activity. In the vasculature, it binds preferentially to re-
gions of newly developing microcalcification because the sur-
face area of hydroxyapatite in these nanocrystalline regions is
at its highest. By contrast in regions of macrocalcification,
much of the hydroxyapatite is internalised and not available
for binding [57]. In aortic stenosis, 18F-fluoride acts as a mark-
er of calcification activity correlating with histological staining
for alkaline phosphatase (r = 0.65) and osteocalcin (r = 0.68)
[52] and predicts where novel regions of macroscopic calcium
are going to form (Fig. 3). Tracer uptake increases with more
advanced aortic stenosis [58], offers powerful prediction of
disease progression at 1 and 2 years, of small incremental value
to computed tomography [52, 59], and acts as an independent
predictor of adverse clinical events [59]. This technique holds
promise in better understanding the role of calcification in
aortic stenosis, for example, a recent PET study demonstrated
that whilst calcification activity in aortic stenosis is greater than
inflammation, the reverse is true in atherosclerosis, potentially
explaining the different effects of statins in these two condi-
tions [60]. With further improvement, 18F-fluoride PET may
Fig. 2 Survival of patients with aortic stenosis under medical treatment
according to valvular calcium score. Patients with severe absolute
calcification (a) or calcification indexed to body surface area (b) had
increased all-cause mortality compared to patients with non-severe
calcification. Indeed, severe aortic valve calcification (AVC) was an
independent predictor of survival following adjustment for age, sex,
presence of coronary artery disease or diabetes, indexed aortic valve area
and ejection fraction. Reproduced from Clavel et al. [53••] with
permission from Elsevier/Journal of the American College of Cardiology
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prove of clinical use in identifying patients likely to progress
rapidly towards surgery and as a marker of disease activity and
efficacy end point in clinical trials of novel therapies (e.g.
SALTIRE 2: NCT02132026).
18F-FDG
18F-FDG PET is widely used to image vascular inflammation.
This PET tracer is a glucose analogue, which accumulates in
metabolically active cells such as vascular macrophages.
Indeed, an excellent correlation between macrophage burden
on histology (CD68 staining on immunohistochemistry) in
carotid atheroma [61] and the 18F-FDG signal has been ob-
served. In aortic stenosis, 18F-FDG activity is higher in pa-
tients versus controls, demonstrating a modest correlation
with severity of valvular disease [58]. Of interest, no correla-
tion with CD68 staining of explanted valves was observed
suggesting that 18F-FDG uptake is occurring in other metabol-
ically active cells, although this study was limited by a low
sample size [52]. Perhaps, the biggest limitation of this tech-
nique is the effect of physiological myocardial 18F-FDG up-
take, which frequently contaminates signal originating from
the aortic valve.
CMR
Cardiac magnetic resonance is an emerging technology that
offers excellent spatial resolution, functional assessment and
the unique ability to provide myocardial tissue characterisa-
tion. However, it remains an expensive modality with limited
availability for cardiac patients in most centres,
LV Mass and Hypertrophy
CMR provides the gold-standard assessment of LV volumes
and mass and allows detailed investigation of both the degree
of hypertrophy and the different patterns of the left ventricular
adaption. Importantly, the myocardial hypertrophic response is
only weakly correlated with the hemodynamic severity of aor-
tic stenosis [16, 62, 63], with males generally display a greater
increase in LV mass even after correction for body size [16].
Classically, wall thickening occurs in a concentric pattern, but
recent studies have shown that asymmetrical patterns also exist
in around a quarter of patients assessed by CMR [16]. The
clinical importance of this observation remains unclear.
Myocardial Fibrosis
Myocardial fibrosis is a key mechanism driving the progres-
sion from the left ventricular hypertrophy to heart failure and
death in aortic stenosis [64]. Historically, it has only been
appreciated using invasive endomyocardial biopsy tech-
niques, but this carries a small but significant risk of compli-
cations [65] and is susceptible to sampling error. CMR pro-
vides a non-invasive assessment of whole-heart fibrosis using
two techniques: late gadolinium enhancement (LGE) and T1
mapping (Fig. 4).
LGE
This technique was first described in 1999 [66] and involves
the intravenous administration of gadolinium-based contrast
agents (GBCA). These agents alter myocardial T1 values and
enter healthy myocardium from the blood pool down a con-
centration gradient within 1–3 min (wash-in phase). Renal ex-
cretion of GBCA from the blood pool then produces a reverse
concentration gradient with myocardial GBCA concentrations
declining over the ensuing 10–30 min (wash-out phase). The
large molecular size of gadolinium stops GBCA from crossing
cell membranes, so that they effectively label the extracellular
space and accumulate in regions of replacement fibrosis due to
delayed wash-out [67]. These focal areas can then be detected
using T1-weighted sequences 15–20 min after contrast admin-
istration. In aortic stenosis, areas of replacement fibrosis appear
as bright areas in the mid-wall of the left ventricle in contrast to
surrounding healthymyocardium [68]. Areas of previousmyo-
cardial infarction, which are common in AS patients, are also
detected by this technique but can be differentiated from mid-
wall replacement fibrosis by their subendocardial/transmural
pattern and their coronary distribution.
Mid-wall replacement fibrosis as detected by LGE is com-
mon in aortic stenosis (29–62 % of patients depending on the
population studied [69, 70•, 71•]) and seems to be irreversible
following valve intervention [72]. The presence of LGE cor-
relates with histological fibrosis [73•] and evidence of
Fig. 3 18F-fluoride PET activity predicts the development of new
calcific deposits in the aortic valve on repeat CT imaging performed
after 1 year. Example imaging from two patients (a and b) are shown
below. Baseline non-contrast CT images (left) showed evidence of in-
creased 18F-Fluoride PET activity (middle) in areas where subsequent
calcification was observed on repeat CT scanning after 1 year (right).
Reproduced from Pawade et al. [3] with permission from Elsevier/
Journal of the American College of Cardiology
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myocardial injury (as measured by high sensitivity troponin I
concentrations) [74]. Advanced mid-wall fibrosis identifies
patients that do not gain improvement in LV systolic function
[73•] or overall functional status following AVR [72].
Importantly, three studies have confirmed that the presence
of LGE acts as an independent predictor of all-cause mortality
[70•, 71•, 73•], increasing the risk of death up to eightfold
[70•]. Mid-wall fibrosis therefore appears to be a direct marker
of the left ventricular decompensation in aortic stenosis and
may be of use in identifying patients whose ventricle are
starting to fail and who might benefit from prompt AVR.
Further research on this area is needed; indeed, EVoLVeD-
AS a multicentre randomised-controlled trial assessing the
benefit of early surgery in patients with advanced aortic ste-
nosis and mid-wall fibrosis on CMR is due to the start enroll-
ing patients next year.
Diffuse Fibrosis
The non-invasive assessment of diffuse fibrosis is more chal-
lenging. Its homogeneous nature means that it is missed on
LGE techniques, which rely on regions of normal myocardium
to generate contrast. However, the detection of diffuse fibrosis
is important because it is widely believed to be reversible [75]
and the precursor to irreversible forms of replacement fibrosis.
Myocardial T1 mapping techniques enable the calculation
of a specific T1 relaxation time (native T1) for each CMR
voxel which can then be displayed on a 2D map with colour
overlays applied for easier visual analysis. Multiple different
techniques have been developed (Table 1). Full examination
of these techniques is beyond the scope of this article, but
further information can be found in this recent review by
Moon et al. [76]. In brief, native T1 measurements can be
made without the need for contrast, an important potential
advantage especially in subjects with severe renal dysfunction
who are at risk of contrast-induced nephrogenic systemic fi-
brosis (NSF) [77]. GBCA can also be used to generate post-
contrast T1 maps as gadolinium shortens T1 relaxation times.
In principle, these images provide greater signal but they are
influenced by individual variation in gadolinium kinetics and
have suffered from poor reproducibility when studied in AS
populations [78•]. Importantly, these variations in kinetics can
be corrected using several approaches. The partition coeffi-
cient (λ) is calculated as a ratio of myocardial to blood post-
contrast T1 values, which improves reproducibility and cor-
rects for many confounders. At gadolinium contrast equilibri-
um, the contrast concentration in the blood and myocardium
should be equal. Calculating the blood volume of distribution
(1—haematocrit) enables the myocardial volume of distribu-
tion to be deduced, also termed the extracellular volume frac-
tion (ECV). Because ECV predominantly comprises collagen
and is increased in fibrotic states, it acts as a marker of myo-
cardial fibrosis, correlating closely with the collagen volume
fraction on histology [79–82].
Although native T1 and ECV have been extensively stud-
ied in the literature, results are mixed and interpretation is
confounded by heterogenous studied populations, variations
in T1 mapping sequence, CMR scanner, magnetic field
strength and analytical technique (e.g. inclusion or exclusion
of areas of LGE).
Native T1 values appear to correlate with histological myo-
cardial fibrosis [83, 84] as well as global longitudinal strain
Fig. 4 Cardiac magnetic
resonance imaging in a patient
with severe aortic stenosis.
Predominant asymmetrical
hypertrophy of the anteroseptum
is seen with associated patchy
mid-wall late gadolinium
enhancement (LGE, red arrows).
These areas are also identified
visually using native and post-
contrast T1 maps (white arrows)
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[84], LV mass, haemodynamic assessments of severity and
patient functional status [83]. However, its ability to differen-
tiate healthy patients from controls is dependent on the popu-
lation studied [78•, 83] with a significant degree of overlap in
T1 values between these groups particularly subjects with less
advanced stenosis. In a population of non-ischaemic dilated
cardiomyopathy patients, native T1 has recently been shown
to be an independent predictor of all-cause mortality and heart
failure events [85] although this has not been demonstrated in
aortic stenosis patients.
ECV
The extracellular volume fraction is used as a surrogate for the
extracellular space, which is expanded with collagen deposi-
tion in diffuse fibrosis. Our centre has demonstrated superior
intra- and inter-observer and scan-rescan variability in aortic
stenosis compared to the other T1 measures, and ECV corre-
lates with LV diastolic dysfunction [78•] and functional status
[86]. However, prognostic data is currently lacking. There is
also significant overlap between ECV values obtained in
healthy volunteers and AS patients, and normal ECV values
have been observed in a hypertensive population (another
condition characterised by LV pressure overload) [87].
Another disadvantage is that ECV measures fibrosis rela-
tive to the volume (or mass) of the left ventricle. Balanced
increases in both LVmass and diffuse fibrosis with progressive
aortic stenosis are therefore not detected using this approach.
In fact, an important study by Krayenbeuhl et al. involving
serial myocardial biopsies demonstrated that histological myo-
cardial fibrosis as a percentage of the myocardium (which is
estimated by ECV calculation on CMR) actually increased
early following aortic valve surgery as a result of significant
reduction in LVmass with no change in the amount of fibrosis.
However, the overall fibrous content (which can be estimated
on CMR by fibrosis volume; ECV × end-diastolic myocardial
volume) did eventually decrease at a later stage (repeat biopsy
an average of 70 months post AVR) [75]. This is partly sup-
ported by a recent CMR study which found that ECV did not
change at 6 months following AVR, whereas there was signif-
icant regression of cellular hypertrophy [86]. There is however
no CMR data regarding late regression of diffuse fibrosis mea-
sures. We believe the use of the fibrosis volume as a measure
of absolute fibrosis may better reflect disease progression and
be able to track changes across interval scans, although this
requires investigation in prospective studies.
Clinical Risk Score
CMR is an expensive technique with limited availability in
many centres. We have devised a clinical risk score [88] based
on five readily measured variables: age, sex, peak aortic valve
velocity, high sensitivity troponin I concentration and pres-
ence of LV strain pattern on ECG, which is highly predictive
of the presence of mid-wall replacement fibrosis on CMR and
mortality. Ultimately, this could be used clinically in place of
CMR imaging or as a screening tool for LV decompensation
in aortic stenosis.
Valve Assessment
CT imaging is able to detect macroscopic calcium deposits in
the aortic valve but is unable to identify fibrosis or lipid depo-
sition, which are key components in the stenotic valve. CMR
offers superior tissue characterisation as demonstrated in a
proof of concept study where 30 explanted aortic valves were
scanned ex-vivo and compared with histological analysis.
CMR showed excellent sensitivity and specificity for the iden-
tification of both mineralisation (calcification) and fibrosis,
with lower accuracy for lipid-rich tissues [89]. Although this
is an exciting field for further research, in vivo imaging with
this approach is not currently feasible due to leaflet motion.
Table 1 T1 mapping measures available for assessment of myocardial fibrosis
Measure Unit Calculation Advantages Limitations
Native T1 ms T1 relaxation curve No gadolinium requirement
(can use in severe renal failure)
T1 signal represented a composite of
myocardium and extracellular space
Post-contrast T1 ms T1 relaxation curve following
gadolinium administration
Improved sensitivity in identifying
myocardial fibrosis
Significant variability due to individual
variation in gadolinium kinetics and
time to imaging post-contrast injection
Partition coefficient (λ) Ratio Ratio of T1 signal change
(pre- and post-contrast) in
myocardium and blood pool
Excellent scan-rescan reproducibility Does not account for plasma volume of
distribution of gadolinium contrast
Extracellular volume
fraction (ECV)
% ECV= λ × (1—haematocrit) Excellent scan-rescan reproducibility.
Conceptually attractive measure
Gives a measure of relative fibrosis
which may not best track changes in
aortic stenosis
Fibrosis volume ml ECV× end-diastolic volume Quantitative measure of absolute
fibrosis volume
Limited evidence at current time
May require indexing to body size to
enable comparison between individuals
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Aortic Regurgitation
Echocardiography
TTE remains the first-line imaging modality in the investiga-
tion of patients with aortic regurgitation, allowing assessment
of mechanism, valve morphology and severity of regurgita-
tion as well as measures of LV remodelling and function.
Imaging of the aortic root and ascending aorta is essential,
although in patients with poor acoustic windows, cross-
sectional imaging may be required for accurate assessment.
The assessment of aortic regurgitation severity is more nu-
anced than aortic stenosis, requiring the integration of differ-
ent visual, semi-quantitative and quantitative parameters as
recommended by clinical guidelines [5, 6]. Visual assessment
of the valve leaflets allows appreciation of prolapse or non-
coaptation, whilst the length and width of the regurgitant jet
on colour Doppler gives a qualitative impression of severity.
Whilst useful, these measures correlate onlymodestly with the
following more objective measures of AR severity which also
require assessment [90].
Semiquantitative Parameters
Calculating the ratio of the regurgitant jet width to that of the
LVOT gives a semiquantitative measure of AR severity (se-
vere if >65 %) [91]. The vena contracta (the narrowest part of
the regurgitant jet) can also be measured, and a width of
>0.6 cm suggests severe AR. Both these techniques are limit-
ed by a single plane of assessment and the assumption of a
circular regurgitant orifice. 3D TTEmay therefore allow more
accurate measurements [92].
Doppler-Based Measures
Although continuous wave AR Doppler jet density is a poor
marker of severity, the rate of deceleration (pressure half-time,
PHT) is a useful adjunct to other measures. A value of
<200 ms is considered severe with measurements critically
dependent on obtaining an aligned Doppler signal. PHT is best
used in addition to other parameters as it is affected by LV
compliance, blood pressure and usually reduced in acute AR
of any severity. Doppler assessment of aortic flow direction is
highly useful where imaging windows allow. Holodiastolic
flow reversal in the descending aorta, especially when associ-
ated with an end-diastolic velocity of >20 cm/s, is specific but
not sensitive for severe AR [93].
Quantitative Parameters
Calculation of effective regurgitant orifice area (EROA) or
regurgitant volume (RV) is possible in some patients using
the flow-convergence zone (PISA) method, which is less
sensitive to loading conditions than other measures and also
useful if the jet is eccentric. It is however less well studied than
in mitral regurgitation, assumes a circular orifice (with a hemi-
spheric flow convergence zone) and is impossible to measure
in a substantial proportion of patients [90]. An alternative is
the regurgitant fraction (RF), which can be calculated by the
Doppler volumetric method. This involves comparing the sys-
temic stroke volume (calculated by assessing the flow over
either the mitral or pulmonary valves assuming no significant
valvular regurgitation) with the total stroke volume (calculated
from LVOT flow.) This is time-consuming and the potential
for compounding multiple small measurement errors can lead
to substantial overall inaccuracies. Again, the use of 3D TTE
may be superior in calculating regurgitant fraction [94].
LV Dimensions and Function
The response of the LV to chronic volume overload is cham-
ber dilatation and hypertrophy. Left ventricular end-systolic
diameter (LVESd) is an independent predictor of the develop-
ment of cardiac symptoms or LV dysfunction [95, 96] and the
risk of progression or mortality approaches 20 % when
LVESd >5.0 cm [97]. LV systolic impairment occurs late in
the disease process and is associated with poor prognosis [98]
which is improved following AVR [99]. Current clinical
guidelines advise valve intervention for asymptomatic severe
AR in the presence of significant LV dilatation (LVESd
>5.0 cm) or LV systolic impairment [5, 6]. Other measures
of LV function such as global strain and strain rate may detect
earlier decompensation, and further research on outcomes is
needed [100–103].
TOE
As with aortic valve replacement for aortic stenosis,
transoesophageal echocardiography is frequently used (with
significant variation between centres) both pre- and intraoper-
atively to aid in prosthesis sizing, confirm satisfactory pros-
thesis functioning and detect immediate post-operative com-
plications. In centres with appropriate expertise, TOE also
allows detailed assessment of valve morphology permitting
valve preserving repair procedures in selected patients, partic-
ularly those with aortic root aneurysms or regurgitant non-
calcified bicuspid valves [104].
CMR
As discussed, CMR provides the gold-standard assessment of
LV volumes and ejection fraction [105]. Perhaps unsurprising-
ly, therefore, left ventricular dilatation detected by CMR (end-
diastolic volume (EDV) >246ml) has shown strong predictive
ability for the future development of symptoms and need for
valve surgery in AR [106••]. However, CMR is also able to
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determine the aortic regurgitant volume to a high degree of
accuracy using phase-contrast velocity mapping. This map,
created in an orthogonal plane to that of aortic flow (usually
at the level of the sinotubular junction [107]), encodes flow to
each voxel and covers the whole cardiac cycle. It can therefore
be used to calculate both anterograde and retrograde flow
(and ultimately regurgitant volume and fraction, Fig. 5).
It shows superior reproducibility to echocardiography
[108] and excellent correlation with both TTE assess-
ment [109] and invasive measures of stroke volume
[110]. There is some debate as to the optimal cut-off in
the regurgitant fraction to define severe regurgitation. A
value of 50 % as used in TTE would seem logical, but
there is evidence of superior discrimination at a lower
value of 30 % [111] and a RF above 33 % strongly
predicted the need for surgery within 3 years in a series
of 113 patients [106••]. Although there are some techni-
cal reasons why a discrepancy may exist, further work is
required to corroborate this single centre study and to
demonstrate improvement in patient outcomes using this
more expensive imaging modality. However, there may
be a place for CMR assessment of aortic regurgitation in
clinical practice when there is diagnostic uncertainty as
to severity of regurgitation.
Conclusions
Aortic valve imaging is a rapidly expanding and exciting
field. Although transthoracic echocardiography has limi-
tations, it remains the first-line imaging modality of
choice. However, other techniques are emerging which
provide complimentary information and may aid clinical
decision-making. In particular, CT can quantify the cal-
cium burden in aortic stenosis as an alternative measure
of disease severity. CMR can quantify the aortic
regurgitant volume and provide detailed assessment of
the hypertrophic response whilst PET can directly mea-
sure disease activity in the valve. Further research is
required to investigate the role that these approaches
may play in the future, where incremental clinical benefit
to standard echocardiographic approaches will need to be
demonstrated.
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Fig. 5 Phase-contrast velocity mapping for aortic regurgitation
quantification. The slice location for through plane measurement is
shown on a three chamber still image (top) with a jet of aortic
regurgitation visible (white arrow). Through plane images are shown
(middle) in systole depicting magnitude (left) and flow (middle) and
diastole showing regurgitation in black (right). Regurgitant volume and
fraction can then be calculated from a time-flow curve (bottom). LV left
ventricle, Ao aorta, LA left atrium. Reproduced from Myerson et al.
[106••] with permission from Wolters Kluwer Health, Inc./Circulation
21 Page 10 of 14 Curr Cardiovasc Imaging Rep (2016) 9: 21
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG,
Enriquez-Sarano M. Burden of valvular heart diseases: a
population-based study. Lancet. 2006;368:1005–11.
2. Carabello BA. Introduction to aortic stenosis. Circulation
Research. Lippincott Williams & Wilkins; 2013;113:179–85.
3. Pawade TA, Newby DE, Dweck MR. Calcification in aortic ste-
nosis: the skeleton key. J Am Coll Cardiol. 2015;66:561–77.
4. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis.
JACC. Elsevier Inc; 2012;60:1854–63.
5. Joint task force on the management of valvular heart disease of the
European Society of Cardiology (ESC), European Association for
Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O,
Andreotti F, Antunes MJ, et al. Guidelines on the management
of valvular heart disease (version 2012). European Heart
Journal. The Oxford University Press; 2012. pp. 2451–96.
6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP,
Guyton RA, et al. 2014 AHA/ACC guideline for the management
of patients with valvular heart disease: executive summary: a re-
port of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. Circulation.
Lippincott Williams & Wilkins; 2014. pp. 2440–92.
7. Lancellotti P, Donal E, Magne J, Moonen M, O’Connor K,
Daubert J-C, et al. Risk stratification in asymptomatic moderate
to severe aortic stenosis: the importance of the valvular, arterial
and ventricular interplay. Br Heart J. BMJ Publishing Group Ltd
and British Cardiovascular Society; 2010;96:1364–71.
8. Connolly HM, Oh JK, Orszulak TA, Osborn SL, Roger VL,
Hodge DO, et al. Aortic valve replacement for aortic stenosis with
severe left ventricular dysfunction. Prognostic indicators.
Circulation. 1997;95:2395–400.
9. Connolly HM, Oh JK, Schaff HV, Roger VL, Osborn SL, Hodge
DO, et al. Severe aortic stenosis with low transvalvular gradient
and severe left ventricular dysfunction:result of aortic valve re-
placement in 52 patients. Circulation. 2000;101:1940–6.
10. Rask LP, Karp KH, Eriksson NP. Flow dependence of the aortic
valve area in patients with aortic stenosis: assessment by application
of the continuity equation. J Am Soc Echocardiogr. 1996;9:295–9.
11. Minners J, AllgeierM,Gohlke-Baerwolf C, Kienzle R-P, Neumann
F-J, Jander N. Inconsistent grading of aortic valve stenosis by cur-
rent guidelines: haemodynamic studies in patients with apparently
normal left ventricular function. Heart. BMJ Publishing Group Ltd
and British Cardiovascular Society; 2010;96:1463–8.
12. Clavel M-A, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf
J, Araoz PA, et al. The complex nature of discordant severe calci-
fied aortic valve disease grading: new insights from combined
Doppler echocardiographic and computed tomographic study. J
Am Coll Cardiol. 2013;62:2329–38.
13. Tribouilloy C, Levy F, Rusinaru D, Guéret P, Petit-Eisenmann H,
Baleynaud S, et al. Outcome after aortic valve replacement for
low-flow/low-gradient aortic stenosis without contractile reserve
on dobutamine stress echocardiography. J Am Coll Cardiol.
2009;53:1865–73.
14. Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray
S, et al. Low-flow aortic stenosis in asymptomatic patients:
valvular-arterial impedance and systolic function from the SEAS
Substudy. JACC Cardiovasc Imaging. 2009;2:390–9.
15. Kusunose K, Goodman A, Parikh R, Barr T, Agarwal S, Popovic
ZB, et al. Incremental prognostic value of left ventricular global
longitudinal strain in patients with aortic stenosis and preserved
ejection fraction. Circ Cardiovasc Imaging. 2014;7:938–45.
16. Dweck MR, Joshi S, Murigu T, Gulati A, Alpendurada F, Jabbour
A, et al. Left ventricular remodeling and hypertrophy in patients
with aortic stenosis: insights from cardiovascular magnetic reso-
nance. J Cardiovasc Magn Reson. 2012;14:1–1.
17.• Cioffi G, Faggiano P, Vizzardi E, Tarantini L, Cramariuc D,
Gerdts E, et al. Prognostic effect of inappropriately high left
ventricular mass in asymptomatic severe aortic stenosis. Heart.
BMJ Publishing Group Ltd and British Cardiovascular
Society; 2011;97:301–7. This is the first paper suggesting
that increased LV mass is an independent predictor of out-
come in aortic stenosis.
18. Duncan AI, Lowe BS, Garcia MJ, Xu M, Gillinov AM,
Mihaljevic T, et al. Influence of concentric left ventricular remod-
eling on early mortality after aortic valve replacement. Ann
Thorac Surg. 2008;85:2030–9.
19. Orsinelli DA, Aurigemma GP, Battista S, Krendel S, Gaasch WH.
Left ventricular hypertrophy and mortality after aortic valve re-
placement for aortic stenosis. A high risk subgroup identified by
preoperative relative wall thickness. JACC. 1993;22:1679–83.
20.•• Gerdts E, Rossebø AB, Pedersen TR, Cioffi G, Lønnebakken MT,
CramariucD, et al. Relation of left ventricular mass to prognosis in
initially asymptomatic mild to moderate aortic valve stenosis. Circ
Cardiovasc Imaging. 2015;8:e003644. This large prospective
study showed that increased LV mass is a predictor of cardio-
vascular event and all-cause mortality independent of age, sex,
ejection fraction and presence of hypertension.
21. Monin J-L, Quéré J-P, Monchi M, Petit H, Baleynaud S, Chauvel
C, et al. Low-gradient aortic stenosis: operative risk stratification
and predictors for long-term outcome: a multicenter study using
dobutamine stress hemodynamics. Circulation. Lippincott
Williams & Wilkins; 2003;108:319–24.
22. Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano
ST, Holmes DR. Low-output, low-gradient aortic stenosis in pa-
tients with depressed left ventricular systolic function: the clinical
utility of the dobutamine challenge in the catheterization laborato-
ry. Circulation. 2002;106:809–13.
23. Levy F, Laurent M, Monin J-L, Maillet JM, Pasquet A, Le
Tourneau T, et al. Aortic valve replacement for low-flow/low-gra-
dient aortic stenosis operative risk stratification and long-term
outcome: a European multicenter study. J Am Coll Cardiol.
2008;51:1466–72.
24. de Filippi CR,Willett DL, BricknerME, Appleton CP, Yancy CW,
Eichhorn EJ, et al. Usefulness of dobutamine echocardiography in
distinguishing severe from nonsevere valvular aortic stenosis in
patients with depressed left ventricular function and low
transvalvular gradients. Am J Cardiol. 1995;75:191–4.
25. Quéré J-P, Monin J-L, Levy F, Petit H, Baleynaud S, Chauvel C,
et al. Influence of preoperative left ventricular contractile reserve
on postoperative ejection fraction in low-gradient aortic stenosis.
Circulation. Lippincott Williams & Wilkins; 2006;113:1738–44.
26. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-
flow, low-gradient severe aortic stenosis despite preserved ejection
fraction is associated with higher afterload and reduced survival.
Circulation. Lippincott Williams & Wilkins; 2007;115:2856–64.
27.•• Dayan V, Vignolo G, Magne J, Clavel M-A, Mohty D, Pibarot P.
Outcome and impact of aortic valve replacement in patients with
preserved LVEF and low-gradient aortic stenosis. J Am Coll
Cardiol. 2015;66:2594–603. This meta-analysis provides the
strongest evidence to date of increased mortality and survival
benefit of AVR in patients with low-flow low-gradient severe
aortic stenosis. Similar findings in patients with normal-flow
Curr Cardiovasc Imaging Rep (2016) 9: 21 Page 11 of 14 21
low-gradient severe aortic stenosis are novel and require fur-
ther research.
28. Eleid MF, Sorajja P, Michelena HI, Malouf JF, Scott CG, Pellikka
PA. Flow-gradient patterns in severe aortic stenosis with preserved
ejection fraction: clinical characteristics and predictors of survival.
Circulation. Lippincott Williams & Wilkins; 2013;128:1781–9.
29. Clavel M-A, Dumesnil JG, Capoulade R, Mathieu P, Sénéchal M,
Pibarot P. Outcome of patients with aortic stenosis, small valve
area, and low-flow, low-gradient despite preserved left ventricular
ejection fraction. J Am Coll Cardiol. 2012;60:1259–67.
30. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N,
Buellesfeld L, et al. Clinical outcomes of patients with low-flow,
low-gradient, severe aortic stenosis and either preserved or re-
duced ejection fraction undergoing transcatheter aortic valve im-
plantation. European Heart Journal. The Oxford University Press;
2013;34:3437–50.
31. Ozkan A, Hachamovitch R, Kapadia SR, Tuzcu EM, Marwick
TH. Impact of aortic valve replacement on outcome of symptom-
atic patients with severe aortic stenosis with low gradient and
preserved left ventricular ejection fraction. Circulation.
Lippincott Williams & Wilkins; 2013;128:622–31.
32. Mehrotra P, Jansen K, FlynnAW, Tan TC, Elmariah S, PicardMH,
et al. Differential left ventricular remodelling and longitudinal
function distinguishes low flow from normal-flow preserved ejec-
tion fraction low-gradient severe aortic stenosis. European Heart
Journal. The Oxford University Press; 2013;34:1906–14.
33. Jander N, Hochholzer W, Kaufmann BA, Bahlmann E, Gerdts E,
Boman K, et al. Velocity ratio predicts outcomes in patients with
low gradient severe aortic stenosis and preserved EF. Br Heart J.
BMJ Publishing Group Ltd and British Cardiovascular Society;
2014;100:1946–53.
34. Lancellotti P, Lebois F, SimonM, Tombeux C, Chauvel C, Pierard
LA. Prognostic importance of quantitative exercise Doppler echo-
cardiography in asymptomatic valvular aortic stenosis.
Circulation. 2005;112:I377–82.
35. Maréchaux S, Hachicha Z, Bellouin A, Dumesnil JG, Meimoun P,
Pasquet A, et al. Usefulness of exercise-stress echocardiography
for risk stratification of true asymptomatic patients with aortic
valve stenosis. European Heart Journal. The Oxford University
Press; 2010;31:1390–7.
36. Saura D, de la Morena G, Flores-Blanco PJ, Oliva MJ, Caballero
L, González-Carrillo J, et al. Aortic valve stenosis planimetry by
means of three-dimensional transesophageal echocardiography in
the real clinical setting: feasibility, reliability and systematic devi-
ations. Echocardiography. 2015;32:508–15.
37. Qizilbash B, Couture P, Denault A. Impact of perioperative trans-
esophageal echocardiography in aortic valve replacement. Semin
Cardiothorac Vasc Anesth. SAGE Publications; 2007;11:288–
300.
38. Michelena HI, Abel MD, Suri RM, Freeman WK, Click RL,
Sundt TM, et al. Intraoperative echocardiography in valvular heart
disease: an evidence-based appraisal. Mayo Clin Proc. 2010;85:
646–55.
39. Ionescu AA, West RR, Proudman C, Butchart EG, Fraser AG.
Prospective study of routine perioperative transesophageal echo-
cardiography for elective valve replacement: clinical impact and
cost-saving implications. J Am Soc Echocardiogr. 2001;14:659–
67.
40. Flachskampf FA, Wouters PF, Edvardsen T, Evangelista A, Habib
G, Hoffman P, et al. Recommendations for transoesophageal echo-
cardiography: EACVI update 2014. Eur Heart J - Cardiovasc
Imaging. 2014;15:353–65.
41. Hahn RT, Little SH,MonaghanMJ, Kodali SK,WilliamsM, Leon
MB, et al. Recommendations for comprehensive intraprocedural
echocardiographic imaging during TAVR. JACC Cardiovasc
Imaging. 2015. pp. 261–87.
42. Wang H, Hanna JM, Ganapathi A, Keenan JE, Hurwitz LM,
Vavalle JP, et al. Comparison of aortic annulus size by transesoph-
ageal echocardiography and computed tomography angiography
with direct surgical measurement. Am J Cardiol. 2015;115:1568–
73.
43. Tsuneyoshi H, Komiya T, Shimamoto T. Accuracy of aortic annu-
lus diameter measurement: comparison of multi-detector CT,
Two- and three-dimensional echocardiography. J Card Surg.
2016;31:18–22.
44. Altiok E, Koos R, Schröder J, Brehmer K, Hamada S, Becker M,
et al. Comparison of two-dimensional and three-dimensional im-
aging techniques for measurement of aortic annulus diameters
before transcatheter aortic valve implantation. Heart. BMJ
Publishing Group Ltd and British Cardiovascular Society;
2011;97:1578–84.
45.•• Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M,
et al. Predictors of outcome in severe, asymptomatic aortic steno-
sis. N Engl J Med. 2000;343:611–7. This seminal paper sug-
gested the strong prognostic importance of aortic valve calci-
fication, outperforming traditional assessment of hemody-
namic severity.
46.•• Rosenhek R, Klaar U, SchemperM, Scholten C, Heger M, Gabriel
H, et al. Mild andmoderate aortic stenosis. Natural history and risk
stratification by echocardiography. Eur Heart J. The Oxford
University Press; 2004;25:199–205. The value of using the
above echocardiography-based calcium scoring system was
subsequently demonstrated in patients with mild and moder-
ate AS.
47. Messika-Zeitoun D, AubryM-C, Detaint D, Bielak LF, Peyser PA,
Sheedy PF, et al. Evaluation and clinical implications of aortic
valve calcification measured by electron-beam computed tomog-
raphy. Circulation. Lippincott Williams & Wilkins; 2004;110:
356–62.
48. Cowell SJ, Newby DE, Burton J, White A, Northridge DB, Boon
NA, et al. Aortic valve calcification on computed tomography
predicts the severity of aortic stenosis. Clin Radiol. 2003;58:
712–6.
49. Cueff C, Serfaty J-M, Cimadevilla C, Laissy J-P, Himbert D,
Tubach F, et al. Measurement of aortic valve calcification using
multislice computed tomography: correlation with haemodynamic
severity of aortic stenosis and clinical implication for patients with
low ejection fraction. Heart. BMJ Publishing Group Ltd and
British Cardiovascular Society; 2011;97:721–6.
50. Messika-Zeitoun D, Bielak LF, Peyser PA, Sheedy PF, Turner ST,
Nkomo VT, et al. Aortic valve calcification: determinants and
progression in the population. Arterioscler. Thromb. Vasc. Biol.
Lippincott Williams & Wilkins; 2007;27:642–8.
51. Nguyen V, Cimadevilla C, Estellat C, Codogno I, Huart V,
Benessiano J, et al. Haemodynamic and anatomic progression of
aortic stenosis. Br Heart J. BMJ Publishing Group Ltd and British
Cardiovascular Society; 2015;101:943–7.
52. Dweck MR, Jenkins WSA, Vesey AT, Pringle MAH, Chin CWL,
Malley TS, et al. 18F-sodium fluoride uptake is a marker of active
calcification and disease progression in patients with aortic steno-
sis. Circ Cardiovasc Imaging. Lippincott Williams & Wilkins;
2014;7:371–8.
53.•• Clavel M-A, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf
J, Aggarval S, et al. Impact of aortic valve calcification, as mea-
sured by MDCT, on survival in patients with aortic stenosis: re-
sults of an international registry study. J Am Coll Cardiol.
2014;64:1202–13. This multicentre observational study
showed that previously defined sex-specific values for severe
aortic stenosis based on CT assessment of aortic valve calcifi-
cation provided incremental prognostic information beyond
echo-derived measures.
21 Page 12 of 14 Curr Cardiovasc Imaging Rep (2016) 9: 21
54. Aksoy O, Cam A, Agarwal S, Ige M, Yousefzai R, Singh D, et al.
Significance of aortic valve calcification in patients with low-
gradient low-flow aortic stenosis. Clin Cardiol. Wiley
Periodicals, Inc; 2014;37:26–31.
55. Clavel M-A, Malouf J, Messika-Zeitoun D, Araoz PA, Michelena
HI, Enriquez-Sarano M. Aortic valve area calculation in aortic
stenosis by CT and Doppler echocardiography. JACC
Cardiovasc Imaging. 2015;8:248–57.
56. Chin CWL, Khaw HJ, Luo E, Tan S,White AC, Newby DE, et al.
Echocardiography underestimates stroke volume and aortic valve
area: implications for patients with small-area low-gradient aortic
stenosis. Can J Cardiol. 2014;30:1064–72.
57. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JLE, Dweck MR,
et al. Identifying active vascular microcalcification by (18)F-sodi-
um fluoride positron emission tomography. Nat Commun. Nature
Publishing Group; 2015;6:7495.
58. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H,
White A, et al. Assessment of valvular calcification and inflam-
mation by positron emission tomography in patients with aortic
stenosis. Circulation. Lippincott Williams & Wilkins; 2012;125:
76–86.
59. Jenkins WSA, Vesey AT, Shah ASV, Pawade TA, Chin CWL,
White AC, et al. Valvular (18)F-fluoride and (18)F-
fluorodeoxyglucose uptake predict disease progression and clini-
cal outcome in patients with aortic stenosis. J Am Coll Cardiol.
2015;66:1200–1.
60. Dweck MR, Khaw HJ, Sng GKZ, Luo ELC, Baird A, Williams
MC, et al. Aortic stenosis, atherosclerosis, and skeletal bone: is
there a common link with calcification and inflammation?
European Heart Journal. The Oxford University Press; 2013;34:
1567–74.
61. Tawakol A,Migrino RQ, Bashian GG, Bedri S, VermylenD, Cury
RC, et al. In vivo 18F-fluorodeoxyglucose positron emission to-
mography imaging provides a noninvasive measure of carotid
plaque inflammation in patients. J Am Coll Cardiol. 2006;48:
1818–24.
62. Gunther S, Grossman W. Determinants of ventricular function in
pressure-overload hypertrophy inman. Circulation. 1979;59:679–88.
63. Salcedo EE, Korzick DH, Currie PJ, Stewart WJ, Lever HM,
Goormastic M. Determinants of left ventricular hypertrophy in
patients with aortic stenosis. Cleve Clin J Med. 1989;56:590–6.
64. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova
V, et al. Progression from compensated hypertrophy to failure in
the pressure-overloaded human heart: structural deterioration and
compensatory mechanisms. Circulation. 2003;107:984–91.
65. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C,
Athanasiadis A, et al. Comparative evaluation of left and right
ventricular endomyocardial biopsy: differences in complication
rate and diagnostic performance. Circulation. Lippincott
Williams & Wilkins; 2010;122:900–9.
66. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O,
et al. Relationship of MRI delayed contrast enhancement to irre-
versible injury, infarct age, and contractile function. Circulation.
1999;100:1992–2002.
67. de Jong S, van Veen TAB, de Bakker JMT, Vos MA, van Rijen
HVM. Biomarkers of myocardial fibrosis. J Cardiovasc
Pharmacol. 2011;57:522–35.
68. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ.
Visualisation of presence, location, and transmural extent of
healed Q-wave and non-Q-wave myocardial infarction. Lancet.
Elsevier; 2001;357:21–8.
69. Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R,
et al. Noninvasive detection of fibrosis applying contrast-
enhanced cardiac magnetic resonance in different forms of left
ventricular hypertrophy relation to remodeling. J Am Coll
Cardiol. 2009;53:284–91.
70.• DweckMR, Joshi S,Murigu T, Alpendurada F, Jabbour A,Melina
G, et al. Midwall fibrosis is an independent predictor of mortality
in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271–
9. The presence of mid-wall fibrosis on CMR was associated
with an eight-fold increase in all-cause mortality.
71.• Barone-Rochette G, Piérard S, de deMeester Ravenstein C, Seldrum
S,Melchior J,Maes F, et al. Prognostic significance of LGEbyCMR
in aortic stenosis patients undergoing valve replacement. J Am Coll
Cardiol. 2014;64:144–54. Again, mid-wall fibrosis is an indepen-
dent predictor of all-cause mortality following AVR.
72. . Weidemann F, Herrmann S, Störk S, Niemann M, Frantz S,
Lange V, et al. Impact of myocardial fibrosis in patients with
symptomatic severe aortic stenosis. Circulation. Lippincott
Williams & Wilkins; 2009;120:577–84.
73.• Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS,
Sampaio RO, et al. Prognostic significance of myocardial fibrosis
quantification by histopathology and magnetic resonance imaging
in patients with severe aortic valve disease. JACC. 2010;56:278–
87. A key study showing that mid-wall fibrosis is associated
with worse improvement in LV function post-AVR and is an
independent predictor of long-term survival.
74. Chin CWL, Shah ASV, McAllister DA, Joanna Cowell S, Alam S,
Langrish JP, et al. High-sensitivity troponin I concentrations are a
marker of an advanced hypertrophic response and adverse outcomes
in patients with aortic stenosis. Eur Heart J. 2014;35:2312–21.
75. Krayenbeuhl HP, Hess OM, Monrad ES, Schneider J, Mall G,
Turina M. Left-ventricular myocardial structure in aortic-valve
disease before, intermediate, and late after aortic-valve replace-
ment. Circulation. 1989;79:744–55.
76. Higgins DM, Moon JC. Review of T1 mapping methods: com-
parative effectiveness including reproducibility issues. Curr
Cardiovasc Imaging Rep. Springer US; 2014;7:1–10.
77. Khawaja AZ, Cassidy DB, Shakarchi Al J, McGrogan DG, Inston
NG, Jones RG. Revisiting the risks ofMRI with gadolinium based
contrast agents-review of literature and guidelines. Insights
Imaging. Springer Berlin Heidelberg; 2015;6:553–8.
78.• Chin CWL, Semple S, Malley T, White AC, Mirsadraee S, Weale
PJ, et al. Optimization and comparison of myocardial T1 tech-
niques at 3T in patients with aortic stenosis. Eur Heart J-
Cardiovasc Imaging. 2014;15:556–65. This paper demonstrated
superior intra, inter observer and scan-rescan reproducibility
in ECVassessment of patients with aortic stenosis.
79. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM,
Elliott PM, et al. Equilibrium contrast cardiovascular magnetic
resonance for the measurement of diffuse myocardial fibrosis:
preliminary validation in humans. Circulation. Lippincott
Williams & Wilkins; 2010;122:138–44.
80. Fontana M, White SK, Banypersad SM. Comparison of T1 map-
ping techniques for ECV quantification. Histological validation
and reproducibility of ShMOLLI versus multibreath-hold T1
quantification…. J Cardiovasc Magn…. 2012.
81. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V,
Flett AS, et al. T1 mapping for myocardial extracellular volume
measurement by CMR: bolus only versus primed infusion tech-
nique. JACC Cardiovasc Imaging. 2013;6:955–62.
82. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, Aschauer S,
Duca F, Bachmann A, et al. T1 mapping by CMR imaging: from
histological validation to clinical implication. JACC Cardiovasc
Imaging. 2016;9:14–23.
83. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon
M, et al. Human non-contrast T1 values and correlation with his-
tology in diffuse fibrosis. Heart. BMJ Publishing Group Ltd and
British Cardiovascular Society; 2013;99:932–7.
84. Lee S-P, Lee W, Lee JM, Park E-A, Kim H-K, Kim Y-J, et al.
Assessment of diffuse myocardial fibrosis by using MR imaging
Curr Cardiovasc Imaging Rep (2016) 9: 21 Page 13 of 14 21
in asymptomatic patients with aortic stenosis. Radiology.
Radiological Society of North America; 2015;274:359–69.
85. Puntmann VO, Carr-White G, Jabbour A, Yu C-Y, Gebker R,
Kelle S, et al. T1-mapping and outcome in nonischemic cardio-
myopathy: all-cause mortality and heart failure. JACCCardiovasc
Imaging. 2016;9:40–50.
86. Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS,
et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equi-
librium contrast cardiovascular magnetic resonance study.
European Heart Journal - Cardiovascular Imaging. The Oxford
University Press; 2012;13:jes102–826.
87. Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu C-Y,
et al. T1 Mapping in discrimination of hypertrophic phenotypes:
hypertensive heart disease and hypertrophic cardiomyopathy:
findings from the International T1 Multicenter Cardiovascular
Magnetic Resonance Study. Circ Cardiovasc Imaging.
Lippincott Williams & Wilkins; 2015;8:e003285.
88. Chin CWL,Messika-Zeitoun D, Shah ASV, Lefevre G, Bailleul S,
Yeung ENW, et al. A clinical risk score of myocardial fibrosis
predicts adverse outcomes in aortic stenosis. European Heart
Journal. The Oxford University Press; 2015;:ehv525.
89. Le Ven F, Tizón-Marcos H, Fuchs C, Mathieu P, Pibarot P, Larose
E. Valve tissue characterization by magnetic resonance imaging in
calcific aortic valve disease. Can J Cardiol. 2014;30:1676–83.
90. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA,
Edvardsen T, Pierard LA, et al. Recommendations for the echocar-
diographic assessment of native valvular regurgitation: an execu-
tive summary from the European Association of Cardiovascular
Imaging. European Heart Journal - Cardiovascular Imaging.
Oxford University Press; 2013;14:611–44.
91. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B. Evaluation of
aortic insufficiency by Doppler color flow mapping. JACC.
1987;9:952–9.
92. Fang L, Hsiung MC, Miller AP, Nanda NC, Yin WH, Young MS,
et al. Assessment of aortic regurgitation by live three-dimensional
transthoracic echocardiographic measurements of vena contracta
area: usefulness and validation. Echocardiography. Blackwell
Science Inc; 2005;22:775–81.
93. Tribouilloy C, Avinée P, Shen WF, Rey JL, Slama M, Lesbre JP.
End diastolic flow velocity just beneath the aortic isthmus
assessed by pulsed Doppler echocardiography: a new predictor
of the aortic regurgitant fraction. Br Heart J. BMJ Group;
1991;65:37–40.
94. Choi J, Hong G-R, Kim M, Cho IJ, Shim CY, Chang H-J, et al.
Automatic quantification of aortic regurgitation using 3D full vol-
ume color doppler echocardiography: a validation study with car-
diac magnetic resonance imaging. Int J Cardiovasc Imaging.
Springer Netherlands; 2015;31:1379–89.
95. Tornos MP, Olona M, Permanyer-Miralda G, Herrejon MP,
Camprecios M, Evangelista A, et al. Clinical outcome of severe
asymptomatic chronic aortic regurgitation: a long-term prospec-
tive follow-up study. Am Heart J. 1995;130:333–9.
96. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward
JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in
clinical practice. A long-term follow-up study. Circulation.
1999;99:1851–7.
97. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term
assessment of the natural history of asymptomatic patients with
chronic aortic regurgitation and normal left ventricular systolic
function. Circulation. 1991;84:1625–35.
98. Turina J, Milincic J, Seifert B, Turina M. Valve replacement in
chronic aortic regurgitation. True predictors of survival after extend-
ed follow-up. Circulation. 1998;98:II100–6–discussionII106–7.
99. Chaliki HP, Mohty D, Avierinos J-F, Scott CG, Schaff HV, Tajik
AJ, et al. Outcomes after aortic valve replacement in patients with
severe aortic regurgitation and markedly reduced left ventricular
function. Circulation. 2002;106:2687–93.
100. Marciniak A, Sutherland GR, Marciniak M, Claus P, Bijnens B,
Jahangiri M. Myocardial deformation abnormalities in patients
with aortic regurgitation: a strain rate imaging study. Eur J
Echocardiogr. The Oxford University Press; 2009;10:112–9.
101. Smedsrud MK, Pettersen E, Gjesdal O, Svennevig JL, Andersen
K, Ihlen H, et al. Detection of left ventricular dysfunction by
global longitudinal systolic strain in patients with chronic aortic
regurgitation. J Am Soc Echocardiogr. 2011;24:1253–9.
102. Ewe SH, Haeck MLA, Ng ACT, Witkowski TG, Auger D, Leong
DP, et al. Detection of subtle left ventricular systolic dysfunction in
patients with significant aortic regurgitation and preserved left
ventricular ejection fraction: speckle tracking echocardiographic
analysis. European Heart Journal - Cardiovascular Imaging.
Oxford University Press; 2015;16:992–9.
103. Park SH, Yang YA, Kim KY, Park SM, Kim HN, Kim JH, et al.
Left ventricular strain as predictor of chronic aortic regurgitation. J
Cardiovasc Ultrasound. 2015;23:78–85.
104. David TE. Surgical treatment of aortic valve disease. Nat Rev
Cardiol. Nature Publishing Group; 2013;10:375–86.
105. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland
JG, et al. Comparison of left ventricular ejection fraction and vol-
umes in heart failure by echocardiography, radionuclide ventricu-
lography and cardiovascular magnetic resonance; are they inter-
changeable? European Heart Journal. The Oxford University
Press; 2000;21:1387–96.
106.•• Myerson SG, d’Arcy J, Mohiaddin R, Greenwood JP, Karamitsos
TD, Francis JM, et al. Aortic regurgitation quantification using
cardiovascular magnetic resonance: association with clinical out-
come. Circulation. Lippincott Williams & Wilkins; 2012;126:
1452–60. Regurgitant fraction calculated by phase-encoded
velocity mapping can classify AR severity with high accuracy
and is strongly predictive of progression to symptoms or AVR
within 3 years, although the RV cut-off appeared to be lower
that with echocardiography.
107. Chaturvedi A, Hamilton-Craig C, Cawley PJ,Mitsumori LM,Otto
CM, Maki JH. Quantitating aortic regurgitation by cardiovascular
magnetic resonance: significant variations due to slice location
and breath holding. Eur Radiol. Springer Berlin Heidelberg;
2015:1–10.
108. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell
WE, Mitsumori L, et al. Prospective comparison of valve regurgi-
tation quantitation by cardiac magnetic resonance imaging and
transthoracic echocardiography. Circ Cardiovasc Imaging.
Lippincott Williams & Wilkins; 2013;6:48–57.
109. Honda N, Machida K, Hashimoto M, Mamiya T, Takahashi T,
Kamano T, et al. Aortic regurgitation: quantitation with MR im-
aging velocity mapping. Radiology. 1993;186:189–94.
110. Søndergaard L, Lindvig K, Hildebrandt P, Thomsen C, Ståhlberg
F, Joen T, et al. Quantification of aortic regurgitation by magnetic
resonance velocity mapping. Am Heart J. 1993;125:1081–90.
111. Gabriel RS, Renapurkar R, Bolen MA, Verhaert D, Leiber M,
Flamm SD, et al. Comparison of severity of aortic regurgitation
by cardiovascular magnetic resonance versus transthoracic echo-
cardiography. Am J Cardiol. 2011;108:1014–20.
21 Page 14 of 14 Curr Cardiovasc Imaging Rep (2016) 9: 21
